DOJ’s 2026 Health Care Fraud Takedown: Why Pharmacies Should Act Before An Audit Becomes An Investigation

The Department of Justice’s 2026 National Health Care Fraud Takedown should get the attention of every pharmacy owner and operator.

According to the DOJ, the coordinated enforcement action involved 455 defendants and more than $6.5 billion in allegedly false claims. The cases spanned 56 federal districts and 45 states and territories. The government also reported more than $182 million in asset seizures.

For pharmacies, however, the more important point is how the government built the cases.

The case summaries show prosecutors and regulators comparing claims data against drug purchases, inventory, dispensing records, prescriber patterns, patient information, marketing arrangements and controlled-substance records. When those records do not line up, what begins as an invoice request, payment review or PBM audit can become a fraud investigation.

The Government Is Following the Drug

Several cases begin with a straightforward question: did the pharmacy lawfully acquire and dispense the drug for which it billed?

In Hawaii, the government alleged that a pharmacy billed Medicare for drugs it did not dispense and lacked sufficient inventory to support claims for certain high-cost products. In Michigan, prosecutors charged participants in an alleged “pharmacy shortage” scheme involving approximately $1.9 million in claims unsupported by adequate inventory. In New York, authorities alleged that pharmacies received more than $12 million for prescriptions that were not dispensed or were filled using products obtained from unlicensed black-market suppliers.

These allegations go directly to records every pharmacy should be able to produce and explain such as wholesaler invoices, proof of delivery, purchase reports, inventory records, prescription files, reversals and claims data.

These should sound familiar to pharmacy owners dealing with PBM audits. Invoice shortages, purchase-to-dispense reconciliations and sourcing questions may carry consequences beyond a contractual recoupment dispute. The same facts can be reviewed by a PBM special investigations unit or government enforcement agency.

An apparent shortage does not necessarily establish fraud. Legitimate explanations may include timing differences, partial fills, returns, reversals, secondary supplier purchases, central-fill arrangements or reporting errors. The government often reports or press releases settlements with pharmacies as “drugs not dispensed” even in cases where correct medications were dispensed but under incorrect NDC numbers. These are clerical errors, not fraud, and the correct drugs were dispensed to the patient. Still, incorrect NDC’s can present audit issues and potential False Claims Act cases.

High Reimbursement and Rapid Growth Invite Scrutiny

In California, the government alleged that participants exploited a temporary suspension of prior-authorization requirements during a transition in Medi-Cal’s prescription-drug payment system. The alleged scheme caused approximately $269 million in claims to be submitted through a pharmacy for medically unnecessary, high-reimbursement drugs, resulting in nearly $179 million in payments.

The lesson is not that pharmacies should avoid profitable products or legitimate reimbursement opportunities. It is that unusual growth must have a defensible explanation. A pharmacy should be able to establish why utilization increased, who selected the drug, whether the prescriber exercised independent judgment, how patients came to the pharmacy, whether the products were dispensed and whether anyone was compensated based on volume.

Data analytics make these patterns easier to identify. A spike in one product, prescriptions concentrated among a few prescribers, unusual refill timing or claims exceeding apparent purchases may be identified before anyone contacts the pharmacy. By the time an audit letter or subpoena arrives, the reviewing agency may already have a theory.

Prescriber and Marketing Relationships Remain High Risk

In New Jersey, DOJ alleged that a pharmacy owner paid providers to issue prescriptions for high-reimbursement medications selected by the pharmacy, causing approximately $20.7 million in losses to Medicare and Medicaid.

A facially valid prescription does not end the inquiry. Investigators will ask who selected the product, who recruited the patient, whether the prescriber made an independent medical decision and whether compensation influenced the transaction. They will review marketing agreements, consulting arrangements, service fees, rebates, copayment practices and payment flows.

Pharmacy owners should be cautious when a marketer promises access to patients, prescribers or a “turnkey” program involving a high-margin product. Some arrangements are legitimate, but others may create exposure under the Anti-Kickback Statute, False Claims Act, state law and PBM contracts.

Controlled-Substance Compliance Is an Ownership Issue

In Mississippi, the government filed a civil complaint alleging that a pharmacy and its owner could not account for approximately 11,853 controlled substance pills. A separate Mississippi matter involved alleged recordkeeping and inventory failures at a weight clinic relating to more than 433,000 controlled-substance doses.

Inventory controls, loss reporting, access restrictions and discrepancy investigations must work in practice. A policy that employees do not follow offers little protection during an inspection. Unexplained losses and recurring count discrepancies should be escalated promptly.

The immediate threat may also be administrative. A DEA action, state board proceedings, payment suspension or PBM termination can threaten the business before a criminal case is filed.

The First Response Often Shapes the Case

During the representation of pharmacies in PBM audits, fraud, waste and abuse investigations and network disputes, the same mistake is often seen: the pharmacy treats the initial request as routine and allows staff to respond before anyone understands the legal significance.

Invoices are produced without reconciliation. Spreadsheets contain errors. Employees speculate. Explanations change. Records are sent without context. An incomplete first response then becomes the foundation for a larger inquiry.

Not every audit requires a full internal investigation. But a request involving high-dollar products, invoice sufficiency, non-dispensing allegations, patient recruitment, prescriber relationships, controlled substances or possible kickbacks should be evaluated by experienced pharmacy counsel before the pharmacy responds.

Counsel can help preserve records, define the issue, reconcile claims to purchases and dispensing, correct inaccuracies and determine whether repayment, disclosure or other action is appropriate. The objective is not to obstruct an audit but to ensure that the response is complete, accurate and defensible.

What Pharmacies and Plan Sponsors Should Do Now

Pharmacies should conduct the type of reconciliation a government agency or payor is likely to perform. Review high-risk products and unexplained claim growth. Compare purchases, inventory and dispensing. Examine marketer and prescriber relationships. Test controlled substance controls. Escalate PBM fraud, waste and abuse notices rather than treating them as ordinary correspondence.

Plan sponsors should also demand usable claims data, meaningful PBM reporting, enforceable audit rights and clear escalation procedures. Summary reporting may not reveal whether suspicious billing is being identified, overpayments are being recovered or affiliated providers are receiving appropriate scrutiny.

The 2026 takedown does not mean every discrepancy is fraud. Pharmacies operate in a complicated reimbursement system, and legitimate transactions can look suspicious without context. But that context must be documented and presented coherently.

A pharmacy that waits until a payment suspension, termination notice or subpoena arrives has already surrendered valuable ground.

 When high-dollar billing grows quickly, invoices do not reconcile, a marketer promises prescription volume or controlled-substance counts are off, the time to involve experienced pharmacy counsel is before the problem hardens into the government’s theory of the case.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.